CA Patent

CA2733795C — Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives

Assigned to Pfizer Inc · Expires 2013-12-31 · 12y expired

What this patent protects

Compounds of Formula (A) and Formula (B), and crystals comprising compounds of Formula (4A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).The…

USPTO Abstract

Compounds of Formula (A) and Formula (B), and crystals comprising compounds of Formula (4A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).The compounds and crystals are useful for the prevention and treatment of obesity and its associated co-morbidities, in particular type II(type 2) diabetes. (see formula A) (see formula B) (see formula 4A).

Drugs covered by this patent

Patent Metadata

Patent number
CA2733795C
Jurisdiction
CA
Classification
—
Expires
2013-12-31
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.